VR Logo

Erasca Inc. (ERAS) download report


Healthcare | Biotechnology & Pharma Research

Erasca Inc. (ERAS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

IPO Date: 16-Jul-2021

Co-Founder, Chairman & CEO: Dr. Jonathan E. Lim M.D.

Gen. Counsel & Corp. Sec.: Mr. Ebun S. Garner J.D., Esq.

Listing: NASDAQ: ERAS

Country: United States

Headquarters: San Diego, CA

Website: https://www.erasca.com

Key Facts

Market cap: $722.62 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-141.21 Mln

Cash: $392.53 Mln

Total Debt: $29.43 Mln

Insider's Holding: 18.19%

Liquidity: Low

52 Week range: $4.52 - 24.47

Shares outstanding: 121,858,000

Stock Performance

Time Period Erasca (ERAS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-63.99-8.99-17.14
1 month1.26-3.40-4.85
3 months-42.70-7.57-12.74
1 Year--0.18-16.37
3 Years--10.237.97
5 Years--11.366.33
10 Years--12.0710.54
As on 27-Jun-2022 *As on 28-Jun-2022